

MSC-INHP-QHCP-1: Questioner to Health Care Professionals and Regulatory Authorities (Questioner to HCPs and RAs, Study MSC-INHP-8797)

First published: 11/03/2015

Last updated: 23/04/2024

Study

Planned

Administrative details

EU PAS number

EUPAS8797

Study ID

8798

DARWIN EU® study

No

Study countries

Hungary

Poland

Switzerland

Türkiye

United Kingdom

Study description

The aim and objective of the Study MSC-INHP-8797 addressed to health care professionals and regulatory authorities is to measure current and future standard care of cancer therapy and monitor patient outcome. The Study MSC-INHP-8797 examines and follows up on current and future work ethics, beliefs and knowledge regarding marketing, distribution, prescription, and use of drugs in a society, with special emphasis on patient outcome i.e the resulting medical, social and economic consequences of new drug developments such as “The Biosimilars” .

Study status

Planned

Research institutions and networks

Institutions

Best Care Consulting

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Networks

Contact details

Study institution contact

Zsuzsanna Csutor z.csutor@bestcareconsulting.com

Study contact

z.csutor@bestcareconsulting.com

Primary lead investigator

Zsuzsanna Csutor

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 11/03/2015

Study start date

Planned: 11/03/2015

Date of interim report, if expected

Planned: 11/06/2015

Date of final study report

Planned: 11/06/2020

Sources of funding

- Pharmaceutical company and other private sector
- Other

More details on funding

Best Care Consulting, MSC-INHPs

Regulatory

Was the study required by a regulatory body?

No

Methodological aspects

Study type

Study type list

Study type:

Not applicable

Scope of the study:

Drug utilisation

Main study objective:

Study MSC-INHP-8797 addressed to health care professionals and regulatory authorities is to measure current and future standard care of cancer therapy and monitor patient outcome attributed by newly developed drugs such as

Biosimilars.

Study drug and medical condition

Medical condition to be studied

HER2 positive breast cancer

Colorectal cancer metastatic

Glioblastoma

Non-Hodgkin's lymphoma

Additional medical condition(s)

metastatic or recurrent non-small cell lung cancer, advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer

Population studied

Age groups

- Children (2 to < 12 years)
 - Adolescents (12 to < 18 years)
 - Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Estimated number of subjects

1000

Study design details

Data analysis plan

Epidemiological methods shall be used for the analysis of the collected data.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Other](#)

Data sources (types), other

Prospective patient-based data collection, The data will be collected via Questioner in "Google form" for easy and fast and timeless collection of data

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No